Unity Biotechnology Company
Unity Biotechnology finds solutions against age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burdens for individuals, their families, and broader communities. By targeting age-related diseases, we believe that UNITY can treat these diseases, as well as contain healthcare costs and lessen the emotional and societal burden that comes with an aging population.
Investors
Connections from
Total Funding:
210.6M
Headquarters:
Brisbane, California, United States
Funding Status:
Series C
Employee Number:
51-100
Estimated Revenue:
$10M to $50M
Last Funding Type:
Series C
Number Of Exists:
51-100
Technology:
Geroscience
Investor Type:
IPO
Last Funding Date:
Mar 19, 2018
Investors Number:
23
Founded Date:
2009
Industry:
Drug Development, Gene therapy